Loading
First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.
Ghayas Issa led and was first author of the AUGMENT-101 phase 1 report in Nature showing the menin inhibitor revumenib produces remissions in heavily pretreated KMT2A-rearranged and NPM1-mutant acute leukaemia, and of the pivotal phase 2 analysis that led to its 2024 approval. He leads menin inhibitor combination trials and studies of resistance (MEN1 mutations) at MD Anderson.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin and the tags aml, menin.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia and the tags aml, targeted-therapy.
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin, Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, MD Anderson Cancer Center, Acute myeloid leukaemia and the tag aml.
Shares Revumenib, Acute myeloid leukaemia and the tag aml.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin.
Shares Revumenib, Menin, Acute myeloid leukaemia.